Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial

Abstract Cyclic high-dose testosterone administration, known as bipolar androgen therapy (BAT), is a treatment strategy for patients with metastatic castration-resistant prostate cancer (mCRPC). Here, we report the results of a multicenter, single arm Phase 2 study (NCT03554317) enrolling 45 patient...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Mark C. Markowski, Mary-Ellen Taplin, Rahul Aggarwal, Laura A. Sena, Hao Wang, Hanfei Qi, Aliya Lalji, Victoria Sinibaldi, Michael A. Carducci, Channing J. Paller, Catherine H. Marshall, Mario A. Eisenberger, David E. Sanin, Srinivasan Yegnasubramanian, Carolina Gomes-Alexandre, Busra Ozbek, Tracy Jones, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Nature Portfolio 2024-01-01
Schriftenreihe:	Nature Communications
Online-Zugang:	https://doi.org/10.1038/s41467-023-44514-2
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!